Wright JJ, Powers AC, Johnson DB. Endocrine toxicities of immune checkpoint inhibitors. Nat Rev Endocrinol. 2021;17(7):389–99.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ghisoni E, Wicky A, Bouchaab H, Imbimbo M, Delyon J, Gautron Moura B, et al. Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: an overlooked aspect in immunotherapy. Eur J Cancer. 2021;149:153–64.

Article  CAS  PubMed  Google Scholar 

Owen CN, Bai X, Quah T, Lo SN, Allayous C, Callaghan S, et al. Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma. Ann Oncol. 2021;32(7):917–25.

Article  CAS  PubMed  Google Scholar 

Imagawa A, Hanafusa T, Awata T, Ikegami H, Uchigata Y, Osawa H, et al. Report of the committee of the japan diabetes society on the research of fulminant and acute-onset type 1 diabetes mellitus: new diagnostic criteria of fulminant type 1 diabetes mellitus (2012). J Diabetes Investig. 2012;3(6):536–9.

Article  PubMed  PubMed Central  Google Scholar 

Baden MY, Imagawa A, Abiru N, Awata T, Ikegami H, Uchigata Y, et al. Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell death-1 therapy. Diabetol Int. 2019;10(1):58–66.

Article  PubMed  Google Scholar 

Tsutsumi C, Imagawa A, Ikegami H, Makino H, Kobayashi T, Hanafusa T, et al. Class II HLA genotype in fulminant type 1 diabetes: a nationwide survey with reference to glutamic acid decarboxylase antibodies. J Diabetes Investig. 2012;3(1):62–9.

Article  CAS  PubMed  Google Scholar 

Lo Preiato V, Salvagni S, Ricci C, Ardizzoni A, Pagotto U, Pelusi C. Diabetes mellitus induced by immune checkpoint inhibitors: type 1 diabetes variant or new clinical entity? Review of the literature. Rev Endocr Metab Disord. 2021;22(2):337–49.

Article  CAS  PubMed  Google Scholar 

Byun DJ, Braunstein R, Flynn J, Zheng J, Lefkowitz RA, Kanbour S, et al. Immune checkpoint inhibitor-associated diabetes: a single-institution experience. Diabetes Care. 2020;43(12):3106–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Homma T, Yoshida N, Tanaka K, Isemura M, Torii S, Kinoshita T, et al. Fulminant type 1 diabetes mellitus caused by long-term nivolumab administration followed by nivolumab plus cabozantinib combination. Chemotherapy. 2023;68(1):44–7.

Article  CAS  PubMed  Google Scholar 

Qiu J, Luo S, Yin W, Guo K, Xiang Y, Li X, et al. Characterization of immune checkpoint inhibitor-associated fulminant type 1 diabetes associated with autoantibody status and ethnic origin. Front Immunol. 2022;14(13):968798.

Article  Google Scholar 

Kawabata Y, Ikegami H. Genetics of fulminant type 1 diabetes. Diabetol Int. 2020;11(4):315–22.

Article  PubMed  PubMed Central  Google Scholar 

Kawabata Y, Ikegami H, Awata T, Imagawa A, Maruyama T, Kawasaki E, et al. Differential association of HLA with three subtypes of type 1 diabetes: fulminant, slowly progressive and acute-onset. Diabetologia. 2009;52(12):2513–21.

Article  CAS  PubMed  Google Scholar 

Inaba H, Kaido Y, Ito S, Hirobata T, Inoue G, Sugita T, et al. Human leukocyte antigens and biomarkers in type 1 diabetes mellitus induced by immune-checkpoint inhibitors. Endocrinol Metab. 2022;37(1):84–95.

Article  CAS  Google Scholar 

Inaba H, Morita S, Kosugi D, Asai Y, Kaido Y, Ito S, et al. Amino acid polymorphisms in human histocompatibility leukocyte antigen class II and proinsulin epitope have impacts on type 1 diabetes mellitus induced by immune-checkpoint inhibitors. Front Immunol. 2023;6(14):1165004.

Article  Google Scholar 

Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017;5(1):95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Naidoo J, Murphy C, Atkins MB, Brahmer JR, Champiat S, Feltquate D, et al. Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology. J Immunother Cancer. 2023. https://doi.org/10.1136/jitc-2022-006398.

Article  PubMed  PubMed Central  Google Scholar 

Husebye ES, Castinetti F, Criseno S, Curigliano G, Decallonne B, Fleseriu M, et al. Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. Eur J Endocrinol. 2022;187(6):G1-21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Arima H, Iwama S, Inaba H, Ariyasu H, Makita N, Otsuki M, et al. Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan endocrine society. Endocr J. 2019;66(7):581–6.

Article  CAS  PubMed  Google Scholar